Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
Weroha SJ, Oberg AL, Ziegler KL, Dakhilm SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P. Weroha SJ, et al. Among authors: haluska p. Gynecol Oncol. 2011 Jul;122(1):116-20. doi: 10.1016/j.ygyno.2011.03.030. Epub 2011 Apr 22. Gynecol Oncol. 2011. PMID: 21514634 Free PMC article. Clinical Trial.
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
Hendrickson AE, Oberg AL, Glaser G, Camoriano JK, Peethambaram PP, Colon-Otero G, Erlichman C, Ivy SP, Kaufmann SH, Karnitz LM, Haluska P. Hendrickson AE, et al. Among authors: haluska p. Gynecol Oncol. 2012 Feb;124(2):210-5. doi: 10.1016/j.ygyno.2011.10.002. Epub 2011 Nov 1. Gynecol Oncol. 2012. PMID: 22047770 Free PMC article. Clinical Trial.
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P. AlHilli MM, et al. Among authors: haluska p. Gynecol Oncol. 2016 Nov;143(2):379-388. doi: 10.1016/j.ygyno.2016.08.328. Epub 2016 Sep 8. Gynecol Oncol. 2016. PMID: 27614696 Free PMC article.
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ. Galanis E, et al. Among authors: haluska pj jr. Cancer Res. 2010 Feb 1;70(3):875-82. doi: 10.1158/0008-5472.CAN-09-2762. Epub 2010 Jan 26. Cancer Res. 2010. PMID: 20103634 Free PMC article. Clinical Trial.
The insulin-like growth factor system in cancer.
Weroha SJ, Haluska P. Weroha SJ, et al. Among authors: haluska p. Endocrinol Metab Clin North Am. 2012 Jun;41(2):335-50, vi. doi: 10.1016/j.ecl.2012.04.014. Endocrinol Metab Clin North Am. 2012. PMID: 22682634 Free PMC article. Review.
Tumorgrafts as in vivo surrogates for women with ovarian cancer.
Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, Sarkaria JN, Karlan BY, Kumar A, Kaufmann SH, Hartmann LC, Haluska P. Weroha SJ, et al. Among authors: haluska p. Clin Cancer Res. 2014 Mar 1;20(5):1288-97. doi: 10.1158/1078-0432.CCR-13-2611. Epub 2014 Jan 7. Clin Cancer Res. 2014. PMID: 24398046 Free PMC article.
Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.
Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P Jr, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, Keeney G, Peng KW, Hartmann LC. Galanis E, et al. Among authors: haluska p jr. Cancer Res. 2015 Jan 1;75(1):22-30. doi: 10.1158/0008-5472.CAN-14-2533. Epub 2014 Nov 14. Cancer Res. 2015. PMID: 25398436 Free PMC article.
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, Boakye-Agyeman F, Kayode O, Flatten KS, Harrell MI, Swisher EM, Poirier GG, Satele D, Allred J, Lensing JL, Chen A, Ji J, Zang Y, Erlichman C, Haluska P, Kaufmann SH. Wahner Hendrickson AE, et al. Among authors: haluska p. Clin Cancer Res. 2018 Feb 15;24(4):744-752. doi: 10.1158/1078-0432.CCR-17-1590. Epub 2017 Nov 14. Clin Cancer Res. 2018. PMID: 29138343 Free PMC article. Clinical Trial.
98 results